SCHEMBL19198299

SCHEMBL19198299

C#CCOc1ccc(-c2nc3c(o2)C(=O)c2ccccc2C3=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP1 O94782 4/20 0.61
USP19 O94966 2/20 0.61
WDR48 Q8TAF3 1/20 0.61
UCHL3 P15374 1/20 0.60
OTUB1 Q96FW1 3/20 0.51
USP2 O75604 2/20 0.51
USP8 P40818 2/20 0.51
USP36 Q9P275 1/20 0.51
GSTP1 P09211 1/20 0.47
CYP1A1 P04798 2/20 0.46
CYP1A2 P05177 2/20 0.46
MAOA P21397 9/20 0.44
MAOB P27338 9/20 0.44
CYP1B1 Q16678 1/20 0.44
ACHE P22303 1/20 0.41
CA12 O43570 2/20 0.40
CA4 P22748 2/20 0.40
CA9 Q16790 2/20 0.40
CA1 P00915 1/20 0.40
PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7808315 0.80 USP1 (0.71) USP1USP19WDR48UCHL3OTUB1
SCHEMBL29629183 0.77 USP1 (1.00) USP1USP19WDR48UCHL3OTUB1
SCHEMBL7808226 0.77 USP1 (1.00) USP1USP19WDR48UCHL3OTUB1
SCHEMBL29629184 0.77 USP1 (1.00) USP1USP19WDR48UCHL3OTUB1
SCHEMBL31276578 0.75 USP1 (1.00) USP1USP19WDR48UCHL3OTUB1
SCHEMBL7815859 0.75 USP1 (1.00) USP1USP19WDR48UCHL3OTUB1
SCHEMBL7968066 0.75 USP1 (0.77) USP1USP19WDR48UCHL3OTUB1
SCHEMBL7808410 0.75 USP1 (0.77) USP1USP19WDR48UCHL3OTUB1
SCHEMBL19225117 0.75 USP1 (0.77) USP1USP19WDR48UCHL3OTUB1
SCHEMBL19220486 0.75 USP1 (0.82) USP1USP19WDR48UCHL3OTUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450281-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-22 US disclosed
US-10450281-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-10-22 US disclosed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed
US-9725425-B1 Compounds and methods for treating cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450281-B1 Compounds and methods for treating cancer USP8, USP2, NEDD8 USP1 7/4885USP19 22/4885WDR48 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.